Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study.
Paller AS, Flohr C, Eichenfield LF, Irvine AD, Weisman J, Soung J, Pinto Correia A, Natalie CR, Rodriguez Capriles C, Pierce E, Reifeis S, Gontijo Lima R, Armengol Tubau C, Laquer V, Weidinger S. Paller AS, et al. Among authors: rodriguez capriles c. Dermatol Ther (Heidelb). 2023 Jul;13(7):1517-1534. doi: 10.1007/s13555-023-00942-y. Epub 2023 Jun 15. Dermatol Ther (Heidelb). 2023. PMID: 37318750 Free PMC article.
Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis: The IXORA-PEDS Randomized Clinical Trial.
Paller AS, Seyger MMB, Magariños GA, Pinter A, Cather JC, Rodriguez-Capriles C, Zhu D, Somani N, Garrelts A, Papp KA; IXORA-PEDS Investigators. Paller AS, et al. Among authors: rodriguez capriles c. JAMA Dermatol. 2022 May 1;158(5):533-541. doi: 10.1001/jamadermatol.2022.0655. JAMA Dermatol. 2022. PMID: 35416908 Free PMC article. Clinical Trial.
Higher rates of skin clearance and efficacy in challenging body areas are associated with better health-related quality of life following ixekizumab maintenance treatment in pediatric patients with plaque psoriasis.
Hebert AA, Bobonich MA, Rodriguez Capriles C, Gallo G, Li L, Somani N, Ridenour T, Wang Y, Edson-Heredia E, Becker EM. Hebert AA, et al. Among authors: rodriguez capriles c. Pediatr Dermatol. 2022 Jan;39(1):55-60. doi: 10.1111/pde.14892. Epub 2021 Dec 20. Pediatr Dermatol. 2022. PMID: 34931346 Free PMC article.
Population pharmacokinetic and exposure-efficacy analysis of ixekizumab in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS).
Jackson K, Chua L, Velez de Mendizabal N, Pitou C, Rodriguez Capriles C, Paller AS, Lansang P, Seyger MMB, Papp K; IXORA-PEDS study group. Jackson K, et al. Among authors: rodriguez capriles c. Br J Clin Pharmacol. 2022 Mar;88(3):1074-1086. doi: 10.1111/bcp.15034. Epub 2021 Sep 2. Br J Clin Pharmacol. 2022. PMID: 34378230 Free PMC article.
Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS).
Paller AS, Seyger MMB, Alejandro Magariños G, Bagel J, Pinter A, Cather J, Keller S, Rodriguez Capriles C, Gontijo Lima R, Gallo G, Little CA, Edson-Heredia E, Li L, Xu W, Papp K; IXORA-PEDS study group. Paller AS, et al. Among authors: rodriguez capriles c. Br J Dermatol. 2020 Aug;183(2):231-241. doi: 10.1111/bjd.19147. Epub 2020 Jun 15. Br J Dermatol. 2020. PMID: 32316070 Free PMC article. Clinical Trial.